Background The presence of high-abundance drug-resistant HIV-1 jeopardizes success of
antiretroviral therapy (ART). Despite numerous investigations, the clinical impact of low …

Objectives Clinical relevance of low-frequency HIV-1 variants carrying drug resistance
associated mutations (DRMs) is still unclear. We aimed to study the prevalence of low …

Background Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy
(ART); therefore, its detection is important for patient management. The absence of drug …

Background It is largely unknown how frequently low-abundance HIV drug-resistant variants
at levels under limit of detection of conventional genotyping (< 20% of quasi-species) are …

Several prospective and retrospective studies have shown that genotypic testing for drug-
resistant HIV-1 variants has helped health-care providers better understand patient …

Abstract Background Minor (ie,< 20% prevalence) drug-resistant human immunodeficiency
virus (HIV) variants may go undetected, yet be clinically important Objectives To compare …

Objective: In resource-limited countries, antiretroviral therapy (ART) has been scaled up, but
individual monitoring is still suboptimal. Here, we studied whether or not ART had an impact …

Background Implementation of ultrasensitive HIV drug resistance tests for routine clinical
use is hampered by uncertainty about the clinical relevance of drug-resistant minority …

Context Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-
1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART) …

Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended
to help in the selection of antiretroviral therapy and to prevent virologic failure. There are …